A retrospective report highlighted a rapid platelet recovery in a patient with refractory immune-mediated thrombotic thrombocytopenic purpura after adding caplacizumab. The case adds practical signals around timing and hematologic response in an otherwise hard-to-treat scenario. On the cardiovascular side, a cohort study linked antiplatelet therapy with P2Y12 inhibitors to reduced colorectal cancer mortality in a Swedish registry analysis. The study reported no corresponding reduction in cancer incidence among patients with atherosclerotic cardiovascular disease, suggesting effects may relate to outcomes rather than prevention. Both items point to real-world translational links between hematologic control strategies and patient-level cancer outcomes.